About this Journal Submit a Manuscript Table of Contents
International Journal of Rheumatology
Volume 2009 (2009), Article ID 268569, 10 pages
http://dx.doi.org/10.1155/2009/268569
Research Article

Ankylosing Spondylitis Patients Commencing Biologic Therapy Have High Baseline Levels of Comorbidity: A Report from the Australian Rheumatology Association Database

1Monash Department of Clinical Epidemiology, Cabrini Institute, 183 Wattletree Road, Malvern, VIC 3144, Australia
2Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, VIC 3004, Australia
3Austin Spondylitis Clinic, Austin Health, Studley Road, Heidelberg, VIC 3084, Australia
4Centre of Clinical Research Excellence in Therapeutics, Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, VIC 3800, Australia
5School of Physiotherapy, Curtin University of Technology, WA 6000, Australia
6Department of Rheumatology, St George Hospital, NSW 2217, Australia
7Department of Rheumatology, Royal North Shore Hospital, NSW 2065, Australia
8Institute of Bone and Joint Research, University of Sydney, NSW 2065, Australia

Received 13 April 2009; Accepted 28 May 2009

Academic Editor: Malcolm D. Smith

Copyright © 2009 John Oldroyd et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. British Society for Rheumatology, “BSR guideline for prescribing TNF-alpha blockers in adults with ankylosing spondylitis,” December 2005, http://www.rheumatology.org.uk.
  2. J. C. Davis, D. van der Heijde, M. Dougados, and J. M. Woolley, “Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy,” Arthritis Care and Research, vol. 53, no. 4, pp. 494–501, 2005. View at Publisher · View at Google Scholar
  3. M. M. Ward, “Health-related quality of life in ankylosing spondylitis: a survey of 175 patients,” Arthritis Care and Research, vol. 12, no. 4, pp. 247–255, 1999.
  4. K. Lehtinen, “Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis,” Annals of the Rheumatic Diseases, vol. 52, no. 3, pp. 174–176, 1993.
  5. H. Dagfinrud, K. B. Hagen, and T. K. Kvien, “Physiotherapy interventions for ankylosing spondylitis,” Cochrane Database of Systematic Reviews, no. 1, Article ID CD002822, 2008. View at Publisher · View at Google Scholar
  6. M. Dougados, R. Caporal, P. Doury, et al., “A double blind crossover placebo controlled trial of ximoprofen in as.,” Journal of Rheumatology, vol. 16, no. 8, pp. 1167–1169, 1989.
  7. M. Dougados, A. Gueguen, J.-P. Nakache, et al., “Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial,” Rheumatology, vol. 38, no. 3, pp. 235–244, 1999. View at Publisher · View at Google Scholar
  8. R. G. W. Lambert, D. Salonen, P. Rahman, et al., “Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study,” Arthritis and Rheumatism, vol. 56, no. 12, pp. 4005–4014, 2007. View at Publisher · View at Google Scholar
  9. J. Braun, J. Brandt, J. Listing, et al., “Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial,” The Lancet, vol. 359, no. 9313, pp. 1187–1193, 2002. View at Publisher · View at Google Scholar
  10. J. D. Gorman, K. E. Sack, and J. C. Davis Jr., “Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α,” The New England Journal of Medicine, vol. 346, no. 18, pp. 1349–1356, 2002. View at Publisher · View at Google Scholar
  11. D. van der Heijde, A. Kivitz, M. H. Schiff, et al., “Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial,” Arthritis and Rheumatism, vol. 54, no. 7, pp. 2136–2146, 2006. View at Publisher · View at Google Scholar
  12. J. Zochling, D. van der Heijde, M. Dougados, and J. Braun, “Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis,” Annals of the Rheumatic Diseases, vol. 65, no. 4, pp. 423–432, 2006. View at Publisher · View at Google Scholar
  13. J. Brandt, A. Khariouzov, J. Listing, et al., “Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis,” Arthritis and Rheumatism, vol. 48, no. 6, pp. 1667–1675, 2003. View at Publisher · View at Google Scholar
  14. J. C. Davis Jr., D. van der Heijde, J. Braun, et al., “Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomised, controlled trial,” Arthritis and Rheumatism, vol. 48, no. 11, pp. 3230–3236, 2003. View at Publisher · View at Google Scholar
  15. D. van der Heijde, B. Dijkmans, P. Geusens, et al., “Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT),” Arthritis and Rheumatism, vol. 52, no. 2, pp. 582–591, 2005. View at Publisher · View at Google Scholar
  16. M. Breban, P. Ravaud, P. Claudepierre, et al., “Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment,” Arthritis and Rheumatism, vol. 58, no. 1, pp. 88–97, 2008. View at Publisher · View at Google Scholar
  17. R. Buchbinder, L. March, M. Lassere, et al., “Effect of treatment with biological agents for arthritis in Australia: the Australian Rheumatology Association Database,” Internal Medicine Journal, vol. 37, no. 9, pp. 591–600, 2007. View at Publisher · View at Google Scholar
  18. A. Silman, D. Symmons, D. G. I. Scott, and I. Griffiths, “British society for rheumatology biologics register,” Annals of the Rheumatic Diseases, vol. 62, supplement 2, pp. 28–29, 2003.
  19. L. Carmona and J. J. Gomez-Reino, “On behalf of the BIOBADASER Group. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER,” Arthritis Research & Therapy, vol. 8, p. R72, 2006.
  20. M. L. Hetland, “DANBIO: a nationwide registry of biological therapies in Denmark,” Clinical and Experimental Rheumatology, vol. 23, supplement 5, pp. S205–S207, 2005.
  21. L. Konttinen, R. Tuompo, T. Uusitalo, et al., “Anti-TNF therapy in the treatment of ankylosing spondylitis: the Finnish experience.,” Clinical Rheumatology, vol. 26, no. 10, pp. 1693–1700, 2007. View at Publisher · View at Google Scholar
  22. T. K. Kvien, M. S. Heiberg, E. Lie, et al., “A Norwegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases,” Clinical and Experimental Rheumatology, vol. 23, supplement 5, pp. S188–S194, 2005.
  23. I. Rupp, H. C. Boshuizen, C. E. Jacobi, H. J. Dinant, and G. A. M. van den Bos, “Comorbidity in patients with rheumatoid arthritis: effect on health-related quality of life,” Journal of Rheumatology, vol. 31, no. 1, pp. 58–65, 2004.
  24. L. Carmona, M. A. Descalzo, E. Perez-Pampin, et al., “All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists,” Annals of the Rheumatic Diseases, vol. 66, no. 7, pp. 880–885, 2007. View at Publisher · View at Google Scholar
  25. F. Wolfe, D. M. Mitchell, J. T. Sibley, et al., “The mortality of rheumatoid arthritis,” Arthritis and Rheumatism, vol. 37, no. 4, pp. 481–494, 1994.
  26. K. Hyrich, D. Symmons, K. Watson, and A. Silman, “Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national patient register,” Annals of the Rheumatic Diseases, vol. 65, no. 7, pp. 895–898, 2006. View at Publisher · View at Google Scholar
  27. A. M. Briggs, L. March, M. Lassere, et al., “Baseline comorbidities in an Australian population-based cohort of rheumatoid arthritis patients receiving biological therapy: data from the Australian Rheumatology Association Database (ARAD),” International Journal of Rheumatology, in press.
  28. S. van der Linden, H. A. Valkenburg, and A. Cats, “Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria,” Arthritis and Rheumatism, vol. 27, no. 4, pp. 361–368, 1984.
  29. PBS. Pharmaceutical Benefits Scheme, Australian Government Department of Health and Aging, January 2007, http://www.pbs.gov.au/html/home.
  30. National Institute for Health and Clinical Excellence, “Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis,” June 2008, http://www.nice.org.uk/nicemedia/pdf/TA143QuickRefGuide.pdf.
  31. National Institute for Clinical Excellence, Guidance on the Use of Etanercept and Infliximab for the Treatment of Rheumatoid Arthritis, NICE, London, UK, 2002.
  32. L. C. Perera, K. E. Tymms, B. J. Wilson, et al., “Etanercept in severe active rheumatoid arthritis: first Australian experience,” Internal Medicine Journal, vol. 36, no. 10, pp. 625–631, 2006. View at Publisher · View at Google Scholar
  33. M. P. Staples, M. Elwood, R. C. Burton, J. L. Williams, R. Marks, and G. G. Giles, “Non-melanoma skin cancer in Australia: the 2002 national survey and trends since 1985,” Medical Journal of Australia, vol. 184, no. 1, pp. 6–10, 2006.
  34. D. M. Parkin, S. L. Whelan, J. Ferlay, et al., Cancer Incidence in Five Continents, vol. 8, International Agency for Research on Cancer, Lyon, France, 2002.
  35. J. N. Bouwes Bavinck, D. R. Hardie, A. Green, et al., “The risk of skin cancer in renal transplant recipients in Queensland, Australia: a follow-up study,” Transplantation, vol. 61, no. 5, pp. 715–721, 1996. View at Publisher · View at Google Scholar
  36. R. Buchbinder, M. Barber, L. Heuzenroeder, et al., “Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate,” Arthritis Care and Research, vol. 59, no. 6, pp. 794–799, 2008. View at Publisher · View at Google Scholar
  37. S. Garrett, T. Jenkinson, L. G. Kennedy, H. Whitelock, P. Gaisford, and A. Calin, “A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index,” Journal of Rheumatology, vol. 21, no. 12, pp. 2286–2291, 1994.
  38. J. Ware, M. Kosinski, and S. Keller, SF-36 Physical and Mental Health Summary Scales: A User's Manual, New England Medical Centre, The Health Institute, Boston, Mass, USA, 1994.
  39. G. Hawthorne, J. Richardson, and R. Osborne, “The Assessment of Quality of Life (AQoL) Instrument: a psychometric measure of health-related quality of life,” Quality of Life Research, vol. 8, no. 3, pp. 209–224, 1999. View at Publisher · View at Google Scholar
  40. L. H. Daltroy, M. G. Larson, W. N. Roberts, and M. H. Liang, “A modification of the Health Assessment Questionnaire for the spondyloarthropathies,” Journal of Rheumatology, vol. 17, no. 7, pp. 946–950, 1990.
  41. World Health Organization, International Classification of Disease, WHO, Geneva, Switzerland, 1977.
  42. World Health Organization, International Classification of Diseases for Oncology, WHO, Geneva, Switzerland, 1976.
  43. R. Cote, Ed., Systematized Nomenclature of Medicine, College of American Pathologists, Skokie, Ill, USA, 1980.
  44. M. Oppe, R. Rabin, and F. de Charro, “On behalf of the EuroQoL Group 2007. EQ-5D User Guide,” February 2008, http://www.euroqol.org.
  45. R. Ariza-Ariza, B. Hernandez-Cruz, and F. Navarro-Sarabia, “Physical function and health-related quality of life of Spanish patients with ankylosing spondylitis,” Arthritis Care and Research, vol. 49, no. 4, pp. 483–487, 2003.
  46. W. Kievit, J. Fransen, A. J. M. Oerlemans, et al., “The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice,” Annals of the Rheumatic Diseases, vol. 66, no. 11, pp. 1473–1478, 2007. View at Publisher · View at Google Scholar
  47. H. A. Weiss, S. C. Darby, and R. Doll, “Cancer mortality following X-ray treatment for ankylosing spondylitis,” International Journal of Cancer, vol. 59, no. 3, pp. 327–338, 1994. View at Publisher · View at Google Scholar
  48. N. Feltelius, A. Ekbom, and P. Blomqvist, “Cancer incidence among patients with ankylosing spondylitis in Sweden 1965–1995: a population based cohort study,” Annals of the Rheumatic Diseases, vol. 62, no. 12, pp. 1185–1188, 2003. View at Publisher · View at Google Scholar
  49. J. Askling, L. Klareskog, P. Blomqvist, M. Fored, and N. Feltelius, “Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study,” Annals of the Rheumatic Diseases, vol. 65, no. 9, pp. 1184–1187, 2006. View at Publisher · View at Google Scholar